Trial reportNutrition journal2016
Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial.
Trial report in Nutrition journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Weight Management Program on Body Weight in Individuals Who Are Overweight and Otherwise Healthy
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Effects of the Treatment with Flavonoids on Metabolic Syndrome Components in Humans: A Systematic Review Focusing on Mechanisms of Action.International journal of molecular sciences · 2022Pooled it
- The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial.Scientific reports · 2021Trial
- Hesperidin Reverses Oxidative Stress-Induced Damage in Kidney Cells by Modulating Antioxidant, Longevity, and Senescence-Related Genes.Biomedicines · 2025Article
- Caffeine: a potential mechanism for anti-obesity.Purinergic signalling · 2025Review
- Effects of Citrus Flavanone Hesperidin Extracts or Purified Hesperidin Consumption on Risk Factors for Cardiovascular Disease: Evidence From an Updated Meta-analysis of Randomized Controlled Trials.Current developments in nutrition · 2024Article
- Safety of glucosyl hesperidin as a Novel food pursuant to Regulation (EU) 2015/2283.EFSA journal. European Food Safety Authority · 2024Article
- The Effect of Dietary Interventions on Hypertriglyceridemia: From Public Health to Molecular Nutrition Evidence.Nutrients · 2022Review
- Profound Perturbation in the Metabolome of a Canine Obesity and Metabolic Disorder Model.Frontiers in endocrinology · 2022Article
- Review
- Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability.Nutrients · 2020Review
- Attenuation of Weight Gain and Prevention of Associated Pathologies by Inhibiting SSAO.Nutrients · 2020Review
- Low-dose caffeine administration increases fatty acid utilization and mitochondrial turnover in C2C12 skeletal myotubes.Physiological reports · 2020Article
- Green satsuma mandarin orange (Food science and biotechnology · 2019Article
- Hesperidin: A Therapeutic Agent For Obesity.Drug design, development and therapy · 2019Review
- Hesperidin alleviates zinc oxide nanoparticle induced hepatotoxicity and oxidative stress.BMC pharmacology & toxicology · 2018Article
- Phytochemicals That Influence Gut Microbiota as Prophylactics and for the Treatment of Obesity and Inflammatory Diseases.Mediators of inflammation · 2018Review
- Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial.Nutrition journal · 2017Article
- The Safety of Ingested Caffeine: A Comprehensive Review.Frontiers in psychiatry · 2017Review
- High-throughput allele-specific expression across 250 environmental conditions.Genome research · 2016Article
- Mutagenic, Acute, and Subchronic Toxicity Studies of the Hesperetin-7-Glucoside-β-Cyclodextrin Inclusion Complex.International journal of toxicologyArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have previously shown that a combination of glucosyl hesperidin (G-hesperidin) plus caffeine reduces accumulation of body fat, whereas G-hesperidin or caffeine alone shows little effect on high-fat diet-induced obesity in mice. The aim of this study is to evaluate the anti-obesity effect of G-hesperidin plus caffeine on body fat and serum TG in healthy subjects with moderately high body mass index (BMI) and serum TG. Since we considered that there are individual differences in caffeine sensitivity, we conducted dose-finding study of caffeine combined with G-hesperidin.
methodsSeventy-five healthy subjects with moderately high BMI (24-30 kg/m(2)) and serum TG (100-250 mg/dl) were divided and assigned to 12-week intervention with daily intakes of 500 mg of G-hesperidin with or without 25, 50, or 75 mg of caffeine, or placebo in a randomized double-blind placebo-controlled design .
resultsAfter intervention, decreases in abdominal fat area (AFA), especially subcutaneous fat area (SFA), were significantly greater in the G-hesperidin with 50-mg caffeine group (AFA:-8.4 ± 21.9 v.s. 16.3 ± 34.1 cm(2); p < 0.05, SFA: -9.3 ± 17.1 v.s. 11.2 ± 18.3 cm(2); p < 0.01) and in the G-hesperidin with 75-mg caffeine group (AFA:-17.0 ± 31.4 v.s. 16.3 ± 34.1 cm(2); p < 0.01, SFA: -12.4 ± 18.7 v.s. 11.2 ± 18.3 cm(2); p < 0.01) than in the placebo group. Fat-decreasing effects of G-hesperidin were enhanced dose-dependently by caffeine addition. BMI decreases were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group (-0.56 ± 0.74 v.s. -0.02 ± 0.58 kg/m(2); p < 0.05). G-hesperidin with/without caffeine had no effect on serum TG (p > 0.05 v.s. placebo).
conclusionsThese data suggested that a combination of 500-mg G-hesperidin with 50- or 75-mg caffeine may be useful for the prevention or treatment of obesity.
trial registrationUMIN Clinical Trials Registry 000019241 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.